✦ LIBER ✦

P.3.d.009 Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia

✍ Scribed by X. Langlois; A. Megens; H. Lavreysen; R. Wouters; L. Peeters; P. te Riele; H. Hendrickx; M. Mahieu; M. de Bruyn; G. Macdonald

Book ID: 118597407
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 45 KB
Volume: 20
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(10)70747-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacology of JNJ-37822681, a Specific

Pharmacology of JNJ-37822681, a Specific and Fast-Dissociating D2 Antagonist for the Treatment of Schizophrenia

✍ Langlois, X.; Megens, A.; Lavreysen, H.; Atack, J.; Cik, M.; te Riele, P.; Peete 📂 Article 📅 2012 🏛 American Society for Pharmacology and Experimental 🌐 English ⚖ 611 KB

P.3.c.046 Efficacy and safety of JNJ 378

P.3.c.046 Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia

✍ M. Schmidt; L. Janssens; J. Kent; I. Anghelescu; G. Hüsken; V. Sinha; E. Mannaer 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 62 KB

P.3.a.026 Safety, tolerability and D2 oc

P.3.a.026 Safety, tolerability and D2 occupancy of the fast dissociating D2 antagonist JNJ-37822681 in healthy subjects

✍ M. Schmidt; P. de Boer; E. Mannaert; T. Iersel; L. van Nueten 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

P.3.d.009 F15063, a novel antipsychotic

P.3.d.009 F15063, a novel antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: II. Profile in models predictive of efficacy against positive, negative symptoms and cognitive deficits of schizophrenia

✍ R. Depoortere; L. Bardin; A.L. Auclair; L. Bruins Slot; M.S. Kleven; A. Newman-T 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Remoxipride versus thioridazine in the t

Remoxipride versus thioridazine in the treatment of first episodes of schizophrenia in drug-naive patients: A case for specific, low potency D2 antagonists

✍ T. Lambert; N. Keks; J. McGrath; S. Catts; H. Hustig; K. Vaddadi; G. Burrows; F. 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB

Remoxipride, a substituted benzamide, is a selective D2 antagonist with an atypical neuroleptic profile. Previous studies have demonstrated its antipsychotic efficacy against haloperidol and, more recently, thioridazine. Of the 144 patients enrolled in the Australian remoxipride-thioridazine compara

Bioactive Heterocyclic Compound Classes

Bioactive Heterocyclic Compound Classes (Pharmaceuticals) || Arylpiperidine-Based Dopamine D 2 Antagonists/5-HT 2A Antagonists for the Treatment of Autism, Depression, Schizophrenia, and Bipolar Disorder

✍ Dinges, Jürgen; Lamberth, Clemens 📂 Article 📅 2013 🏛 Wiley-VCH Verlag GmbH & Co. KGaA ⚖ 151 KB